Upload
carrie-fairfax
View
218
Download
1
Embed Size (px)
Citation preview
Multimodality Imaging(MRI, PET, CT, etc..)
Jonathan Dyke, Ph.D.Assistant Research Professor
of Physics in RadiologyCitigroup Biomedical Imaging Center
Weill Cornell Medical College
Sackler Institute for Developmental PsychobiologySummer Lecture Series
July 9, 2009
CyclotronRadiochemistry
Cyclotron design from Ernest Lawrence’s1934 patent application.
#protons + #neutrons = Mass #
Atomic # = # protons (never changes)
Basic HS Chemistry is useful.
What does the atomic # define?
What does the atomic mass define?
Radioisotope Production
16O + p -> 18F + n8 9
Target Material: Purified Water
Production of 18F precursor to FDG
Positron Emission Tomography
“PET” Scan (“DOG” Scan)
Is a positron stuff of fiction?
e+ + e- -> a + b
Courtesy: Brookhaven National Lab
PET: Coincidence Detection
Filtered Back Projection(Key for both PET and CT!)
Courtesy: Univ British Columbia
Clinical Applications of PETAlzheimer’s Disease
Primate - 11C-Raclopride Imaging
Courtesy: Shankar Vallabhajosula, Ph.D.
18F-FDG Lymphoma Study:2-[fluorine-18] fluoro-2-deoxy-D-glucose (FDG)
11C-5-Hydroxytryptophan (5-HTP)
Image Analysis:Standard Uptake Value:
Courtesy: PET/CT in clinical practice By T. B. Lynch, James Clarke
Pre-Tx SUV=15 Post-Tx SUV=2
ComputedTomography“CAT Scan”
Creation of X-RaysCirca 1896
Circa 1900
Circa 2000
X-Ray Tube Construction
X-Ray DensitiesDo the following appear
Dark or light on an X-Ray image?
•Air•Fat
•Bone
CT Hounsfield Units
CT Hardware
Advantages:
1)CT completely eliminates the superimposition of images of structures outside the area of interest. 2) because of the inherent high-contrast resolution of CT, differences between tissues that differ in physical density by less than 1% can be distinguished. 3)data from a single CT imaging procedure consisting of either multiple contiguous or one helical scan can be viewed as images in the axial, coronal, or sagittal planes, depending on the diagnostic task. This is referred to as multiplanar reformatted imaging.
In the ED it’s FAST!
CT Diagnostic Utility:Head:
Chest:
Cardiac:
Abdominal and pelvic:
Extremities:
Trauma, Stroke, Tumor, Biopsy
Lungs, Pneumonia, Emphysema, Embolism
Coronary artery disease (High Dose)
Renal stones, appendicitis, pancreatitis, diverticulitis
Fractures, dislocations.
CT - Stroke
CT PerfusionCBF
CBV
MTTAJNR 2000;21:1441–1449.
CT Radiation DoseDiagnostic Advantage
Vs. Increased Risk Cancer
Assumes linear relationship between radiation dose and cancer risk (Controversial).
Risk for pediatric patients developing cancerfrom CT scan is greater than adults.
~ 500 in every 600,000 scans.“CT is an extremely valuable tool, and nobody should
hesitate to undergo CT when it is indicated.”
•CONTRAST ENHANCEMENTCONTRAST ENHANCEMENT•DIFFUSION IMAGINGDIFFUSION IMAGING•FAST IMAGING METHODSFAST IMAGING METHODS•FUNCTIONAL IMAGINGFUNCTIONAL IMAGING•PERFUSION IMAGINGPERFUSION IMAGING•SPECTROSCOPYSPECTROSCOPY
Advanced MRI Applications
MRI CONTRASTENHANCEMENT
Dia Weakest -1Para Weak ~10Ferro Strong ~25,000Super Strong ~5000
Magnetism of Materials
How does it affect the signal?
•What type of material is Gadolinium?•How many unpaired e- does in Gd-DTPA?•What compound do we detect the effect of contrast on?
Contrast Mechanisms Dictate Method of Studyin Magnetic Resonance Imaging
How does an agent affect relaxation times?
1 = 1 + R1,2 C
T1,2 T10,20
Solomon-Bloembergen Equations (1955)
What factors influence whether the T1 or T2 effect will dominate the MRI signal?
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
Tim e (M inutes)
% S
ign
al In
crea
se Whole Brain
Muscle/Vessel
Clinical Apps:Why are contrast agents
necessary given the excellent resolution of
un-enhanced MRI images?
When is a contrast scan prescribed?
Tumor, Stroke, AngiographyCNS disease
But.. Talk is cheap..
Nephrogenic SystemicFibrosis
MRIDIFFUSIONIMAGING
BASIC DWI PHYSICS
CLINICAL APPLICATIONS
TRACTOGRAPHY
What physical aspects or systems In nature exhibit diffusion?
What principles govern diffusion?
The “Drunken” WalkEinstein – 1905
How far does a drunk walk?<R(t)2>= 2 D t vs. R(t)=
v t
DH O= 3x10-3 mm2/sDbrain = 1x10-3 mm2/s
2
What affect does diffusion have on the MRI signal?
S=S0 e –b D
DWI Atten Brain = 1/(2.782)DWI Atten CSF = 1/(2.782^3)
How can you image diffusionat the cellular level accounting
for patient motion?
Patient motion ~ 1-2mmDiffusion length ~ 10-100m
90o
Excitation
Image
Acquisition
RF
Gx
Gy
Gz
G
180o
G
Pulse Sequence: Spin-Echo Diffusion Weighting
Why the different contrastbetween a DWI & ADC image?
DWI = ADC
Clinical Apps:
Acute AML pre/post Tx*Courtesy: Doug Ballon, 2003
A.W. Song, http://www.biac.duke.edu/education/courses/fall04/fmri/
Isotropic vs. Anisotropic
Diffusion Tensor Imaging
3T MRI – NYP - Tumor
MRFUNCTIONAL
IMAGING
BOLD EFFECT PHYSICS
PHYSIOLOGICAL FACTORS
CLINICAL APPLICATIONS
Roy, C.S., and Sherrington, C.S. 1890. On the regulation of the blood supply of the brain. J. Physiol. 11:85-108. 100 years pass…..
Ogawa, S., Lee, T.M., Nayak, A.S., and Glynn, P. 1990. Oxygenation-sensitive contrast I magnetic resonance image of rodent brain at high magnetic fields. Magn. Reson. Med. 14:68-78.
•Oxyhemoglobin is diamagnetic •Deoxyhemoglobin is paramagnetic •Neuronal activity->Less deoxyhemoglobin•Less susceptibility difference between capillary vessel and brain tissue•Longer T2*•Signal increase in T2* Sequence
How big an increase are we talking about?
How does BOLD really work?
Blood Oxygen LevelDependent Signal
Source: Buxton book Ch 17
Dale & Buckner, 1997
Hemodynamic Response
Repeated Trials – Dale/Buckner 1997
Motor Activation in AFNI
Where do we expect activation?
Cortical mapping in thesurgical suite.
Neuron, 2006,18;643-653. – Courtesy BJ Casey
Clinical Apps:• Improving clinical procedures, e.g.
presurgical planning for brain tumors • Direct: Mapping of functional properties
of adjacent tissue • Indirect: Understanding of likely
consequences of a treatment• Understanding cognition • Studying brain development • Investigating brain physiology• ** Henning – Minimally Conscious
State
MR PERFUSIONIMAGING
Physiologically, what happens when a tracer enters the blood
supply?•What factors influence the distribution and kinetics?
Johns Hopkins – Dept Radiology
T1W – DCE MRIDYNAMIC CONTRAST ENHANCED IMAGING
2D Fast Spoiled Gradient Echo, 12 mm slice, 8/0 slices, TR/TE 8 ms/2 ms, 15.63 kHz RBW, 22 cm FOV, 256 x 128 matrix, 8.56 sec/resolution
1
2 34
0.75
1
1.25
1.5
1.75
2
2.25
0 1 2 3 4 5
Minutes
S/S0
Pediatric Osteogenic Sarcoma: Post-Chemotherapy
Grade IV Responder: 100% Necrotic
1
4
3
2
DCE-MRI & ANGIOGENESIS
•What role does neovasculature fill in tumor growth? (Goldman,1907)
•How far from a vessel can a tumor cell survive? (Thomlinson & Gray,1955)
•Does DCE produce any physiologically significant parameters?
Pharmacokinetic Modeling of Tracer Kinetics(Kety, 1951)
ve dCe(t) = Ktrans (Cp(t)-Ce(t))dt
Cp Cp
kep
InterstitialLesion
kelKin
k12
PlasmaIntravascular
Brix/Hoffman 2 Compartment Model
Gd-DTPA 0.1 mM/kg
Compartmental Model Fits
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 0.5 1 1.5 2 2.5 3
Time (Minutes)
S(t)
/S0-
1
Grade II - 50% Necrotic:A=0.75, kep=5.47/min, kel=0.03/min
Grade IV - 100% Necrotic: A=0.30, kep=2.79/min, kel=-0.21/min
Does this model actually fit real data?
CLINICAL APPS:•Tumors: breast, brain, bone
•Drug Trials: anti-angiogenic
•Arthritis: joint/synovium
•BBB leakage/permeability
T2*W – DSC MRIDYNAMIC SUSCEPTIBILITY
CONTRAST
Representative Perfusion Maps
MTT EPI
CBFCBV
62 year old with left MCA territorial stroke. The perfusion maps show prolonged MTT with corresponding decreased CBF and
CBV.
“Arterial Input Function”
Raw SI-ln(S/S0)
Minutes Minutes
“CT Perfusion is for wimps.”
Difficulties in MRP quantitation.•Delay
•Dispersion•Saturation Effects
•Partial Volume Effects•Susceptibility Masking
•Conversion to Concentration
Refs: van Osch,2000; Rausch,2001; Wu,2003
Cerebral Blood Volume
Cerebral Blood Flow
Mean Transit TimeMTT=CBV/CBF
Central Volume Theorem
dttAIF
dttC
h
hCBV
t
SV
LV
)(
)(1
1
1
)()()( tRtAIFCBFtCt
CBF (ml/100 gm/min)
Normal GM = 39+/-10.3Normal WM = 14.7+/-4.1
Ischemia < 10.0
CBV (ml/100 gm )
Normal GM = 4.4%+/-0.9Normal WM = 2.3%+/-0.4
Ischemia = >6 ml
DWI/PWI Services in Stroke: www.synarc.com
MR SPECTROSCOPY
NMR Active NucleiWhat can we see?
Raw Signal“FID”
FFT
“Chemical Shift”Electron Shielding
Water = 4.7ppmLipid = 1.3 ppm=(4.7-1.3) ppm*127.5MHz = 434 Hz @ 3.0 TeslaT=1/= 2.3 ms (IP, OOP)
NAACHOCRELAC
1H Metabolites
Lac 3 1.32 1.33 doubletPara-PyruvateCH3 1.36Alanine 3 1.47 1.44 doubletArginine 4 1.64Lys 5 1.7 1.69 multipletLeu 3 1.71 1.71 multipletLeu 4 1.71g-aminobutyric acid 3 1.89Lys 3 1.89 1.91 multipletAcetate 2 1.91 1.92 singletArginine 3 1.92Ile 3 1.97 1.96 multipletPro 4 1.99N-Acetyl CH3 2.01N-Acetyl CH3 2.05Glu 3 2.06 2.08 multipletN-Acetyl CH3 2.07 2.16 singletMet S(CH3) 2.13 2.14 singletMet 3 2.14 2.16 multipletGln 3 2.15 2.14 multiplet glutamateGSH Glu 3 2.17 GSSG Glu 3 2.17NAAG Glu 4 2.212-Hydroxy-Glutarat 2.27Val 3 2.27 2.24 multipletg-aminobutyric acid 2 2.3Glu 4 2.34 2.36 multiplet gultamatePyr 4 2.4Succinate 2.4Carnitine 2 2.452-Keto-Glutarat 2.46Gln 4 2.46 2.41 multipletCitrate 2.52 doublet B-Alanine 2 2.55GSSG Glu 4 2.55GSH Glu 4 2.57Citrate 2.62 doublet
g-aminobutyric acid 4 3.022-Keto-Glutarat 3.03Creatine CH3 3.03 3.04 singletPCreatine CH3 3.03Cn CH3 3.07phosphoethanolamine 3.15B-Alanine 3 3.18choline 3.2 singletArginine 5 3.21N(CH3)3 3.21PE (N) 3.21Cysteamine (N) 3.23phospho-choline 3.24 singletCarnitine (CH3) 3.24Glc 2B 3.25Oxal-Acetate 3.25Tau (N) 3.25 3.26 tripletPara-Pyruvate CH2 3.27Phe 3 3.27phosphatidylcholine 3.28 singletglycerophospho ethanolamine (N)3.29Inositol (myo) 5 3.29 3.28 tripletHypotau (S) 3.36Inositol (scyllo) 3.36Pro 5 3.39Glc 4a 3.41 3.40 tripletGlc 4B 3.41 3.42 tripletTau (S) 3.41 3.46 tripletGlycogen 4 3.43Glc 5B 3.44 3.47 dddCarnitine 4 3.45Glc 3B 3.5Glc 2a 3.55 3.54 ddInositol (myo) 1,3 3.55 3.56 doublet of doubletsGly 2 3.56 3.61 singletThr 2 3.58PC (N) 3.59Inositol (myo) 4,6 3.61 3.63 dd
A sampling of 1H metabolites
Ex-vivo Mouse brain perchloric acid extract @ 11.4T
What price is paid in detecting these signals?
Grade IIIGBM
Pre-Tx
Dyke JP, Sanelli PC, Voss HU, Serventi JV, Stieg PE, Schwartz TH, Ballon D,Shungu DC, Pannullo SC. Monitoring the Effects of BCNU Chemotherapy Wafers (Gliadel®) in Glioblastoma Multiforme with Proton Magnetic Resonance Spectroscopic Imaging at 3.0 Tesla. J Neurooncol. 2007 Mar;82(1):103-10.
31P Metabolites@ 3.0 Tesla